Diagnostic Utility of a Cost-Effective Four-Gene Next Generation Sequencing Panel for Predicting Papillary Thyroid Carcinoma in Indeterminate Thyroid Cytology: A Multicenter Study in China.
A four-gene blood test accurately predicts which patients with uncertain thyroid nodules actually have cancer, potentially sparing thousands from unnecessary surgery.
This multicenter Chinese study validates a cost-effective 4-gene NGS panel for predicting papillary thyroid carcinoma in cytologically indeterminate thyroid nodules, a clinical setting where surgery is often unnecessarily performed. If confirmed in broader populations, this panel could reduce unnecessary thyroid surgeries globally while maintaining diagnostic accuracy.
What the study was
- Study design
- Multicenter diagnostic validation study
- Population
- Patients with indeterminate thyroid cytology (Bethesda III/IV)
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Cancer Medicine
Why it surfaced
Multicenter design (Cancer Med); addresses high-volume clinical problem of indeterminate thyroid cytology; cost-effectiveness angle is timely; Chinese-only multicenter limits generalizability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.